The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic ...

This study compares the efficacy and tolerability of paliperidone extended-release with risperidone immediate-release in the treatment of schizophrenia, using propensity score methodology.

This analysis used propensity score matching of subjects from randomized placebo-controlled schizophrenia studies to compare paliperidone ER 6–12 mg/day with risperidone 2–4 mg/day and ...

Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale ...

Meeting Coverage > Psych Congress Video Pearls Low Relapse Rates With Twice-Yearly Schizophrenia Treatment — Every-6-month dosing of paliperidone palmitate was effective and safe up to 3 years ...

Find out how to take Paliperidone Palmitrate(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.

The 335 patent relates to dosing regimens for paliperidone palmitate depot (long-acting) formulations for the treatment of schizophrenia.